Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05768945 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 742,670
- Enrollment target
NCT05768945 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 742,670 participants.
The verdict
NCT05768945 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 742,670 participants
- Enrollment target
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Interventions
- DRUG Semaglutide
- DRUG DPP-4 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742,670 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05768945
The ClinicalTrials.gov registry entry for NCT05768945 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 742,670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT05768945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05768945 about?
NCT05768945 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT05768945?
This trial is currently completed. The enrollment target is 742,670 participants. The study started on 2022-11-30. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05768945?
The interventions under investigation include: Semaglutide (DRUG), DPP-4 inhibitor (DRUG).
Who is sponsoring clinical trial NCT05768945?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.